WHO releases first-ever guidelines for utilizing GLP-1 weight loss medications

The World Health Organization (WHO) has published new recommendations for adults with obesity regarding GLP-1 medications, advising their continuous use over the long term when clinically indicated. Drugs included in the guidance are semaglutide (Wegovy), liraglutide (Saxenda), and tirzepatide (Zepbound).

According to the WHO, these medications alone do not solve the global obesity crisis. Obesity is a chronic condition requiring lifelong management, and the most effective approach combines GLP-1 therapy with structured programs emphasizing balanced nutrition, regular physical activity, and ongoing behavioral counseling to achieve and maintain weight loss.

Dr. Louis Aronne, director of the Comprehensive Weight Control Center at Weill Cornell Medicine, commented to ABC News that the guidance represents a major shift: recognizing obesity early as a chronic disease deserving continuous care is becoming a standard part of healthcare.

The guidance also points to significant challenges, including high costs, limited availability, and unequal access worldwide. The WHO urges governments to create fair and affordable systems to ensure that those with the greatest medical need can access these treatments first. Medications should be used appropriately within a comprehensive treatment plan.

GLP-1 medications often help patients adhere to dietary recommendations by reducing hunger and moderating food cravings. Dr. Aronne explained that many patients find it easier to maintain healthier eating habits as these drugs help them feel full sooner. He also stressed the importance of incorporating resistance training to preserve muscle mass during weight loss, as rapid weight reduction combined with low-calorie intake can lead to muscle loss.

Medicines are most effective when combined with behavioral and dietary changes, Dr. Aronne said. When hunger is controlled, people can finally implement the healthy habits they have been advised to follow for years.

Currently, over 1 billion people worldwide live with obesity, a figure expected to rise to 2 billion by 2030. The WHO indicated that future guidance will prioritize identifying and supporting those with the greatest need. Additionally, the organization recommends that countries revamp their obesity care strategies, improving prevention, treatment, and healthcare infrastructure to tackle this escalating public health issue.

Dr. Aronne added, This marks a generational shift in approach focusing on treating obesity early rather than waiting for complications to develop.

Meredith Montgomery, MD, a pediatrician and pediatric emergency medicine fellow at Monroe Carell Jr. Children's Hospital at Vanderbilt, contributed to the ABC News Medical Unit report.

Commentary: WHO's New Obesity Treatment Guidelines Mark a Critical Shift in Global Health Approach

The World Health Organization's recent publication of new recommendations for managing obesity in adults signifies a crucial turning point in how the medical community views and treats this chronic condition. For years, obesity was primarily considered an issue of individual willpower or lifestyle choices. However, the latest guidelines, which advocate for the long-term use of GLP-1 medications like semaglutide, liraglutide, and tirzepatide, reflect a broader understanding that obesity requires ongoing medical intervention and support.

Dr. Louis Aronne's comments reinforce this shift, emphasizing the importance of recognizing obesity early as a chronic disease. This new perspective could change the way healthcare systems approach prevention and treatment. It's not just about weight loss—it's about sustainable, long-term management through a combination of medication, behavioral change, and proper nutrition. The idea that obesity is a lifelong condition that requires continuous care is now becoming a standard part of medical practice, which could lead to better outcomes for patients in the future.

Nevertheless, the WHO's guidance also highlights several challenges, including the high costs and limited accessibility of GLP-1 drugs, especially in low-income countries. While the medications offer significant benefits, they cannot be the sole solution. The integration of these treatments into comprehensive care plans, along with efforts to improve global healthcare access, will be key to tackling the obesity epidemic effectively. Governments must act to create equitable healthcare systems that prioritize those most in need.

The rising global obesity crisis—currently affecting over 1 billion people worldwide and expected to reach 2 billion by 2030—demands urgent attention. The WHO's call for enhanced prevention strategies and treatment options is a timely reminder that tackling obesity requires coordinated efforts across the globe. As we continue to refine our approach, it is clear that the combination of medication, lifestyle changes, and healthcare infrastructure improvements will be essential in addressing this growing public health challenge.

Sources:

• WHO issues first-ever guidelines for use of GLP-1 weight loss medications